Introduction

A pharmacokinetic (PK) study in patients with impaired renal function should be conducted for most drugs intended for chronic use. Since the release of the FDA Guidance on renal PK studies in 2010, various approaches have been used to assess the impact of renal impairment (RI) on investigational drugs.

 

Access the Poster Here

Contact Us
Call Our Team 

Phone: +1 919 876 9300
Fax: +1 919 876 9360
Toll-Free: +1 866 462 7373

Authors

Mario Tanguay, Ingrid Freije, Fadi Achkar
Syneos Health Clinique, QC, Canada
Faculty of Pharmacy, Université de Montréal, QC, Canada